Cognitive Flexibility in Major Depression in the Course of Pharmacological and Psychotherapeutic Treatment
Summary
Cognitive deficits in major depression seem explicable by the well-recognized concept of impaired neuroplasticity in mood disorders. This concept initially emerged from preclinical evidence that antidepressants phosphorylate and therefore activate the cyclic AMP response element binding protein (CREB) that is essential for synaptic plasticity. Nevertheless, the question remains whether the activation of CREB by antidepressants is relevant for the remission of cognitive deficits in patients. We addressed this issue by investigating the cognitive improvement during treatment with either citalopram or reboxetine because these antidepressants are different in their capacity to increase phosphorylated CREB (pCREB). Besides the pharmacological treatment groups, another group of patients was treated exclusively with psychotherapy.
Timeline
- Start
- 2005-08
- Primary completion
- 2008-08
- Completion
- 2008-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Citalopram | Small molecule | 20 mg | — |
| Subject | Citalopram | Small molecule | 30 mg | — |
| Subject | Reboxetine | Unknown | 4 mg | — |
| Subject | Reboxetine | Unknown | 8 mg | — |
Indications
No indication recorded.